# NCI9673 (NCT02314169)

> Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

No report yet. It can be ordered.

- Drugs tested: nivolumab; nivolumab plus ipilimumab
- Indication: refractory metastatic anal canal squamous cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02314169
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Anal Canal Squamous Cell Carcinoma; Metastatic Anal Canal Carcinoma; Stage IV Anal Cancer AJCC v8
- Interventions: Biospecimen Collection; Computed Tomography; Ipilimumab; Magnetic Resonance Imaging; Nivolumab
- Enrollment: 143
- Primary outcome: Overall Response Rate: Number of Participants With Response (Part A)
- Primary outcome: Progression-free Survival (PFS) (Part B)

## Indexed commentary on NCI9673 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 12
- YouTube: 2
- Podcasts: 1

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nci9673-nct02314169

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02314169", "email": "<work email>"}; the inbox owner confirms by the emailed link.